PCM codes – how and when to use them – ACAAI Member
The four PCM codes are intended to reimburse physicians for the additional work they do caring for high risk, complex patients.
Related Articles
Clinical Trial Resources – ACAAI Member
Welcome to the ACAAI Clinical Trial Resource page which connects physicians to existing clinical trials in allergy, asthma and immunology led by our pharmaceutical partners.…
November issue of Annals focuses on COVID-19 and its long-term effects – ACAAI Member
The November issue of Annals of Allergy, Asthma & Immunology is focused on COVID-19 and its long-term effects.
The Truth About Gluten Allergies
If you feel sick or uncomfortable after eating foods like bread or pasta, you’re not alone. Millions of people struggle with gluten, a protein found…
Prior Authorization Letter Generator: Neffy / Anaphylaxis – ACAAI Member
Create a customized letter for your Neffy prior authorization appeals in just a few easy steps.
ACAAI: Most Syphilis Patients With Penicillin Allergy Have Low Risk for Severe Allergy
FRIDAY, Oct. 25, 2024 (HealthDay News) — Delabeling patients with syphilis who believe they are allergic to penicillin is safe, according to a study presented
Are ‘Elimination Diets’ Much Help Against Child Eczema?
FRIDAY, Oct. 25, 2024 (HealthDay News) — Cutting certain foods from a child’s diet isn’t likely to improve their eczema symptoms, a new study finds.Eczema,…
More Kids With Food Allergies Are Needing Psychological Care – Drugs.com MedNews
Anxiety is driving more children with potentially dangerous food allergies to seek out psychological care, a new study finds. Focusing on one Ohio hospital, the
Dermatology Research: Immune-Mediated Dermatologic Conditions | Incyte.com
Discovering and developing the next generation of dermatology treatments for several immune-mediated conditions, including atopic dermatitis, vitiligo and hidradenitis suppurativa.
FASENRA® (benralizumab) for Severe Eosinophilic Asthma | For HCPs
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.